10.6084/m9.figshare.5127679.v1 Nikam M.D. Nikam M.D. Ritchie J. Ritchie J. Jayanti A. Jayanti A. Bernstein O.A. Bernstein O.A. Ebah L. Ebah L. Brenchley P. Brenchley P. Hutchison A. Hutchison A. Chalmers N. Chalmers N. Mitra S. Mitra S. Supplementary Material for: Acute Arteriovenous Access Failure: Long-Term Outcomes of Endovascular Salvage and Assessment of Co-Variates Affecting Patency Karger Publishers 2015 Arteriovenous access Arteriovenous fistula Arteriovenous shunt Haemodialysis Vascular access thrombosis 2015-03-06 00:00:00 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Acute_Arteriovenous_Access_Failure_Long-Term_Outcomes_of_Endovascular_Salvage_and_Assessment_of_Co-Variates_Affecting_Patency/5127679 <b><i>Aims:</i></b> This study reports long-term outcomes after endovascular salvage (EVS) for acute dialysis fistula/graft dysfunction. <b><i>Methods:</i></b> All patients presenting with acute fistula or graft dysfunction, excluding primary failures, referred for endovascular salvage were included in this single-centre prospective study. <b><i>Results:</i></b> Altogether, 410 procedures were carried out in 232 patients. Overall, the incidence of thrombosis/occlusion (per patient-year) was 0.12 for fistulae and 0.9 for grafts. The anatomical success rate for EVS was 94% for fistulae and 92% for grafts. Primary patency rates for fistulae at 1, 6, 12, 24 and 36 months were 82, 64, 44, 34 and 26%, respectively, whereas secondary patency rates were 88, 84, 74, 69 and 61%, respectively. Primary patency rates for grafts at 1, 6 and 12 months were 50, 14 and 8%. The overall rate of complications was 6% with no incidence of symptomatic pulmonary embolism. In a Cox regression model, upper-arm location of fistula (HR 1.9, p = 0.04, n = 144) was associated with lower primary patency, whereas the presence of thrombosis was associated lower primary (HR 1.9, p = 0.004, n = 144) and secondary patency (HR 3.7, p < 0.001, n = 144). Aspirin therapy was associated with longer primary patency (HR 0.6, p = 0.02, n = 144) and secondary patency (HR 0.58, p = 0.08, n = 144). <b><i>Conclusion:</i></b> EVS is effective but longer-term outcomes are poor. Presence of thrombosis portends poor fistula survival and strategies for prevention need attention. Balloon maceration, our preferred declotting technique, is safe and the most cost-effective method. Aspirin therapy for patients presenting with failure of fistulae deserves further investigation.